Indian pharma is hoping to cash in. Generic firms, such as Biocon, are already offering weight-loss drugs, such as cheaper ...

Wegovy, India’s first injectable semaglutide for chronic weight management, recorded Rs 2.54 crore in sales in June 2025—matching the monthly run rate of Mounjaro (tirzepatide), which posted Rs 50 ...

Weight loss injectables such as Ozempic and Mounjaro are gaining popularity in India But are they a sustainable solution or a ...

While Mounjaro offers clinicians a newer option for patients, themedicine alone is not a solution. (Photo: Getty Images) Mounjaro enters India as weight-loss drug, but doctors warn against misuse ...

India's weight-loss game is getting serious! The country's anti-obesity market is now worth ₹628 crore, and it's climbing ...

Several anti-obesity drugs, including Ozempic, Wegovy and Mounjaro, have created buzz in the Indian markets. But are they really approved for use in India? What are their side-effects? And how much do ...

Eli Lilly's Mounjaro demonstrates significant cardiovascular benefits for Type 2 diabetes patients with heart disease, ...

Indian pharmaceutical firms are gearing up to capitalize on the growing demand for weight-loss drugs, with the market potentially reaching $1bn.

Vials of Eli Lilly's Mounjaro, a tirzepatide injection drug used for treating type 2 diabetes and weight loss, are seen in a fridge at a health clinic in Hyderabad, India, April 14, 2025.

Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 ...

Mounjaro has sold more than 81,570 units in India, totalling about 239.4 million rupees ($2.76 million) as of May, with the drug logging a 60% rise in overall sales between April and May ...

According to data from the research firm PharmaTrac, Mounjaro has sold over 81,570 units in India and made ~$2.76 million in revenue as of May. The drug’s sales increased by 60% between April ...